MMP抑制剂II | 203915-59-7

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: MMP抑制剂II
• 英文名称: MMP inhibitor II
• 英文别名: N-hydroxy-1,3-di-[(4-methoxyphenyl)sulfonyl]-5,5-dimethyl-hexahydro-pyrimidine-2-carboxamide；N-hydroxy-1,3-di-(4-methoxybenzenesulphonyl)-5,5-dimethyl-[1,3]-piperazine-2-carboxamide；N-hydroxy-1,3-bis[(4-methoxyphenyl)sulfonyl]-5,5-dimethyl-1,3-diazinane-2-carboxamide
• CAS: 203915-59-7
• 化学式: C₂₁H₂₇N₃O₈S₂
• 分子量: 513.593
• InChiKey: MCSWSPNUKWMZHM-UHFFFAOYSA-N

物化性质

• 密度：
  1.385±0.06 g/cm3(Predicted)
• 溶解度：
  溶于二甲基亚砜

计算性质

• 辛醇/水分配系数(LogP)：
  1.8
• 重原子数：
  34
• 可旋转键数：
  7
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  159
• 氢给体数：
  2
• 氢受体数：
  10

反应信息

• 作为产物：
  描述：

  二甲基丙二胺 在 氢氧化钾 、 硫酸 、 羟胺 、 三乙胺 作用下， 以 甲醇 、 二氯甲烷 、 苯 为溶剂， 生成 MMP抑制剂II
  参考文献：
  名称：

  发现有效的非手性基质金属蛋白酶抑制剂。

  摘要：

  DOI：

  10.1021/jm980253r

文献信息

• Metalloprotein inhibitors containing nitrogen based ligands
  申请人：Cohen Seth M.

  公开号：US20120135959A1

  公开（公告）日：2012-05-31

  Provided herein metalloproteinase inhibitors containing nitrogen or mixed nitrogen/oxygen donating zinc binding groups. Also provided are pharmaceutical compositions containing the compounds and methods of treating preventing or ameliorating the diseases associated with metalloproteinase activity using the compounds and compositions.

  本文提供了含有氮或混合氮/氧供体锌结合基团的金属蛋白酶抑制剂。还提供了含有这些化合物的药物组合物，以及使用这些化合物和组合物治疗、预防或改善与金属蛋白酶活性相关的疾病的方法。
• Method of treating glioma
  申请人：The Board of Trustees of the Leland Stanford Junior University

  公开号：US10377818B2

  公开（公告）日：2019-08-13

  Methods of treating glioma are provided. Aspects of the invention include administering a therapeutically-effective amount of an agent that inhibits the activity of one or more neuronal activity-regulated proteins selected from: neuroligin-3, brain-derived neurotrophic factor (BDNF), or brevican, to a patient with a glioma. In certain embodiments, the subject methods involve treating a neurological dysfunction, reducing invasion of a glioma cell into brain tissue, and/or reducing the growth rate of a glioma in the patient. Also provided herein are methods for identifying an agent that modulates the mitotic index of a glial cell, and methods for stimulating the proliferation of a glial cell. Kits that find use in practicing the subject methods are also provided.

  本发明提供了治疗胶质瘤的方法。本发明的方面包括向胶质瘤患者施用治疗有效量的抑制选自神经ligin-3、脑源性神经营养因子（BDNF）或brevican的一种或多种神经元活性调节蛋白活性的制剂。在某些实施方案中，该主题方法涉及治疗神经功能障碍、减少胶质瘤细胞对脑组织的侵袭和/或降低患者体内胶质瘤的生长速度。本文还提供了鉴定调节胶质细胞有丝分裂指数的药剂的方法，以及刺激胶质细胞增殖的方法。还提供了可用于实施上述方法的试剂盒。
• 1,3-Diheterocyclic metalloprotease inhibitors
  申请人：The Procter & Gamble Company

  公开号：US20030130271A1

  公开（公告）日：2003-07-10

  The invention provides compounds of formula 1 as described in the claims, or an optical isomer, diastereomer or enantiomer thereof, or a pharmaceutically-acceptable salt, or biohydrolyzable amide, ester, or imide thereof are useful as inhibitors of metalloproteases. Also disclosed are pharmaceutical compositions and methods of treating diseases, disorders and conditions characterized by metalloprotease activity using these compounds or the pharmaceutical compositions containing them.

  本发明提供了式 1 的化合物 1 或其光学异构体、非对映异构体或对映体，或其药学上可接受的盐，或其生物可水解的酰胺、酯或亚胺，可作为金属蛋白酶的抑制剂。 此外，还公开了使用这些化合物或含有这些化合物的药物组合物治疗以金属蛋白酶活性为特征的疾病、失调和病症的药物组合物和方法。
• 1,3-DIHETEROCYCLIC METALLOPROTEASE INHIBITORS
  申请人：THE PROCTER & GAMBLE COMPANY

  公开号：EP0927168B1

  公开（公告）日：2002-11-06
• COMPOSITIONS AND METHODS FOR TREATING ASTHMA AND OTHER LUNG DISORDERS
  申请人：Watson Richard L.

  公开号：US20100008997A1

  公开（公告）日：2010-01-14

  Provided are compositions and methods for treating lung or respiratory disorders or conditions characterized by airflow obstruction or limitation, or a symptom thereof (e.g., asthma, rhinitis, allergic rhinitis, and chronic obstructive pulmonary disease (COPD) and COPD-associated conditions (e.g., bronchitis, emphysema, asthma), emphysema, pneumonia, bronchitis, influenza, SARS, tuberculosis, and whooping cough (pertussis), and the like) in a subject in need thereof by administering a therapeutic composition comprising at least one electrokinetically altered fluid (gas-enriched (e.g., oxygen-enriched) electrokinetic fluids) comprising an ionic aqueous solution of charge-stabilized oxygen-containing nanostructures as disclosed herein. In certain aspects, the methods comprise regulating intracellular signal transduction by modulation of at least one of cellular membranes, membrane potential, membrane proteins (e.g., membrane receptors, (e.g., to G protein coupled receptors, and intercellular junctions)). Additional aspects include therapeutic compositions, and combination treatment methods comprising administration of electrokinetically generated fluid in combination with at least one additional therapeutic agent.